Christopher Peetz Sells 6,837 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 6,837 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $327,629.04. Following the transaction, the chief executive officer now directly owns 125,022 shares in the company, valued at $5,991,054.24. This represents a 5.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $48.54 on Wednesday. The firm has a market capitalization of $2.33 billion, a P/E ratio of -24.03 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock’s 50-day simple moving average is $43.90 and its two-hundred day simple moving average is $41.68. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $49.58.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.57) EPS. As a group, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MIRM has been the topic of a number of recent research reports. Citigroup upped their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird increased their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $57.10.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Amalgamated Bank increased its position in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $69,000. Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $189,000. Finally, ProShare Advisors LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter valued at about $213,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.